Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment
Er Yue(City of Hope), Edward Wenge Wang(City of Hope), Fan Fang(Ministry of Education of the People's Republic of China), Atish Mohanty(Beckman Research Institute), Lorna Rodrı́guez-Rodrı́guez(City Of Hope National Medical Center), Tonya C. Walser(City of Hope), Yanqiao Zhang(Harbin Medical University), Yuanfei Yao(Harbin Medical University), Tamara Mirzapoiazova(City Of Hope National Medical Center), Ling Zhao(Zhengzhou Central Hospital), Guangyu Wang(Tongji University), Ravi Salgia(City Of Hope National Medical Center), Guangchao Yang(Harbin Medical University), Yuman Fong(City Of Hope National Medical Center)
Cited by 11
Related Papers
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
|Journal for ImmunoTherapy of Cancer|2018|1.3k
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551
c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion
|Cancer Research|2007|260
An Analysis of the Expression and Association with Immune Cell Infiltration of the cGAS/STING Pathway in Pan-Cancer
|Molecular Therapy — Nucleic Acids|2018|211